Table 1.

Characteristics of Patients with LUAD Based on TCGA

Characteristic	Levels	Overall
n		535
T stage, n (%)	T1	175 (32.9%)
	T2	289 (54.3%)
	T3	49 (9.2%)
	T4	19 (3.6%)
N stage, n (%)	N0	348 (67.1%)
	N1	95 (18.3%)
	N2	74 (14.3%)
	N3	2 (0.4%)
M stage, n (%)	M0	361 (93.5%)
	M1	25 (6.5%)
Primary therapy outcome, n (%)	PD	71 (15.9%)
	SD	37 (8.3%)
	PR	6 (1.3%)
	CR	332 (74.4%)
Pathologic stage, n (%)	Stage I	294 (55.8%)
	Stage II	123 (23.3%)
	Stage III	84 (15.9%)
	Stage IV	26 (4.9%)
Gender, n (%)	Female	286 (53.5%)
	Male	249 (46.5%)
Race, n (%)	Asian	7 (1.5%)
	Black or African American	55 (11.8%)
	White	406 (86.8%)
Age, n (%)	≤65	255 (49.4%)
	>65	261 (50.6%)
Residual tumor, n (%)	R0	355 (95.4%)
	R1	13 (3.5%)
	R2	4 (1.1%)
Anatomic neoplasm subdivision, n (%)	Left	205 (39.4%)
	Right	315 (60.6%)
Anatomic neoplasm subdivision 2, n (%)	Central Lung	62 (32.8%)
	Peripheral Lung	127 (67.2%)
Number_pack_years_smoked, n (%)	<40	188 (50.9%)
	≥40	181 (49.1%)
Smoker, n (%)	No	75 (14.4%)
	Yes	446 (85.6%)
Age, median (IQR)		66 (59, 72)